Last reviewed · How we verify

Glycopyrrolate Inhalation Solution 200μg

Sunovion Respiratory Development Inc. · Phase 2 active Small molecule Quality 0/100

Glycopyrrolate Inhalation Solution 200μg is a Small molecule drug developed by Sunovion Respiratory Development Inc.. It is currently in Phase 2 development. Also known as: GIS.

At a glance

Generic nameGlycopyrrolate Inhalation Solution 200μg
Also known asGIS
SponsorSunovion Respiratory Development Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Glycopyrrolate Inhalation Solution 200μg

What is Glycopyrrolate Inhalation Solution 200μg?

Glycopyrrolate Inhalation Solution 200μg is a Small molecule drug developed by Sunovion Respiratory Development Inc..

Who makes Glycopyrrolate Inhalation Solution 200μg?

Glycopyrrolate Inhalation Solution 200μg is developed by Sunovion Respiratory Development Inc. (see full Sunovion Respiratory Development Inc. pipeline at /company/sunovion-respiratory-development-inc).

Is Glycopyrrolate Inhalation Solution 200μg also known as anything else?

Glycopyrrolate Inhalation Solution 200μg is also known as GIS.

What development phase is Glycopyrrolate Inhalation Solution 200μg in?

Glycopyrrolate Inhalation Solution 200μg is in Phase 2.

Related